全球標靶治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計標靶治療市場將從 2025 年的 884.2 億美元成長到 2034 年的 1,566.4 億美元，2026 年至 2034 年的複合年成長率為 6.56%。

精準醫療和分子診斷技術的進步正推動全球標靶治療市場快速成長。標靶治療，尤其是在腫瘤領域，旨在特異性攻擊疾病相關的分子通路，同時最大限度地減少對健康組織的損傷。癌症發病率的上升以及基於生物標記的治療方法的日益普及是全球市場成長的主要促進因素。

關鍵成長要素包括增加對基因組學研究的投資以及伴隨診斷技術的開發。製藥公司正加大對單株抗體、激酶抑制劑和基因療法的研發投入。新型標靶治療的監管核准以及對個人化治療方法日益成長的需求，進一步推動了已開發市場和新興市場的市場擴張。

展望未來，在免疫腫瘤學和聯合治療持續創新的推動下，市場預計將穩定成長。臨床試驗計畫的拓展和健保報銷機制的完善將提升病患獲得治療的機會。人工智慧在藥物研發過程中的應用可望縮短研發週期。隨著精準醫療的普及，標靶治療有望主導未來的治療策略。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球標靶治療市場：按類型分類

• 市場分析、洞察與預測
• 單株抗體
• 低分子化合物

第5章 全球標靶治療市場：依應用分類

• 市場分析、洞察與預測
• 乳癌
• 結腸癌
• 白血病
• 肺癌
• 淋巴瘤
• 多發性硬化症
• 腎癌
• 老齡化黃斑部病變（濕性）
• 其他

第6章 全球標靶治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球標靶治療市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Sanofi
  • GlaxoSmithKline Plc
  • Takeda Pharmaceutical Company Ltd
  • Merck & Co. Inc
  • Novartis AG
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Seagen Inc
  • Bayer AG
  • Amgen Inc
  • Bristol-Myers Squibb

The Targeted Therapeutics Market size is expected to reach USD 156.64 Billion in 2034 from USD 88.42 Billion (2025) growing at a CAGR of 6.56% during 2026-2034.

The Global Targeted Therapeutics Market is experiencing rapid expansion due to advancements in precision medicine and molecular diagnostics. Targeted therapies are designed to specifically attack disease-related molecular pathways, particularly in oncology, minimizing damage to healthy tissues. Rising cancer prevalence and increasing adoption of biomarker-based treatment approaches are significantly driving market growth worldwide.

Key growth drivers include growing investments in genomics research and the development of companion diagnostics. Pharmaceutical companies are increasingly focusing on monoclonal antibodies, kinase inhibitors, and gene-based therapies. Regulatory approvals for novel targeted drugs and rising demand for personalized treatment regimens are further strengthening market expansion across developed and emerging regions.

Looking ahead, the market is expected to witness robust growth supported by continuous innovation in immuno-oncology and combination therapies. Expanding clinical trial pipelines and improved reimbursement frameworks will enhance accessibility. Integration of artificial intelligence in drug discovery processes may accelerate development timelines. As precision medicine becomes mainstream, targeted therapeutics will likely dominate future treatment strategies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Monoclonal Antibodies
• Small Molecule

By Application

• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lung Cancer
• Lymphoma
• Multiple Sclerosis
• Renal Cancer
• Wet Age-related Macular Degeneration
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd, Merck Co Inc, Novartis AG, Pfizer Inc, F HoffmannLa Roche Ltd, AstraZeneca, Seagen Inc, Bayer AG, Amgen Inc, BristolMyers Squibb
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TARGETED THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Small Molecule Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TARGETED THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Multiple Sclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Renal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Wet Age-related Macular Degeneration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TARGETED THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL TARGETED THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL TARGETED THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Sanofi
  • 9.2.2 GlaxoSmithKline Plc
  • 9.2.3 Takeda Pharmaceutical Company Ltd
  • 9.2.4 Merck & Co. Inc
  • 9.2.5 Novartis AG
  • 9.2.6 Pfizer Inc
  • 9.2.7 F. Hoffmann-La Roche Ltd
  • 9.2.8 AstraZeneca
  • 9.2.9 Seagen Inc
  • 9.2.10 Bayer AG
  • 9.2.11 Amgen Inc
  • 9.2.12 Bristol-Myers Squibb